Eli Lilly and Co on Friday said early data from the first human study of its next-generation Alzheimer's treatment showed that it lowered levels of toxic amyloid plaques in the brains of people in the earliest stages of the mind-wasting disease. The higher the dose of the antibody drug, the larger the effect, Lilly said. The treatment, remternetug, was given by intravenous infusion but has the possibility of a more convenient method of administration via subcutaneous injection.
As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. And some are considering more complex, patient-specific assessments to determine the best course of action, according to a Reuters review of existing guidelines and interviews with doctors and executives from six medical associations as they contemplate updating their own guidance. U.S. health insurance companies take into account specialist medical guidelines, among other data, in deciding whether to pay for a treatment.
Ozempic is a drug that has been soaring in popularity over the past year. Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk.